Form 4: REGENXBIO CMO Executes Stock Sale via 10b5-1 Plan

REGENXBIO Chief Medical Officer Steve Pakola sold 15,309 shares of common stock at a weighted average price of $11.02.

Summary

• Chief Medical Officer Steve Pakola sold 15,309 shares of REGENXBIO Inc. (RGNX) common stock.
• The transaction occurred on May 11, 2026, at a weighted average price of $11.02 per share.
• The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following the transaction, the reporting person retains beneficial ownership of 232,617 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 mechanism, which is a routine administrative action for corporate insiders.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading by scheduling sales in advance.

Negatives

• The sale represents a reduction in the equity stake held by a key member of the executive leadership team.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's near-term valuation.

Future Outlook

No specific forward-looking guidance regarding company operations or financial performance was provided in this filing.

Management Comments

• The reporting person has committed to providing full information regarding the number of shares and prices at each trade interval upon request to the SEC staff, the issuer, or a security holder.

Industry Context

StockSavvy.ai notes that executive stock sales via 10b5-1 plans are standard practice in the biotechnology sector, allowing officers to diversify holdings without triggering market concerns regarding non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate executives in the pharmaceutical and biotech sectors to manage equity compensation.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

REGENXBIO, RGNX, Insider Trading, Form 4, Biotech, Executive Compensation